Should we reestablish the Lung Cancer Study Group?

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology
• Radiation Oncology
• Pathology
• Biostatistics

Background:

• The Lung Cancer Study Group (LCSG) exemplified a successful multidisciplinary approach to thoracic malignancy management.
• This collaborative model integrated thoracic surgeons, medical oncologists, radiation oncologists, pathologists, biostatisticians, and data managers.

Purpose of the Study:

• To evaluate the impact of the Lung Cancer Study Group's (LCSG) discontinuation on thoracic oncology research and clinical trials.
• To assess the effectiveness of current mechanisms in sustaining the work initiated by the LCSG.

Main Methods:

• Analysis of the effects of funding cessation for the LCSG.
• Evaluation of the success of intergroup mechanisms in continuing clinical trials.
• Assessment of the impact on early-stage thoracic malignancies, translational research, and oncologic education.

Main Results:

• Discontinuation of LCSG funding led to the dispersal of expertise and adverse effects on clinical trials and research.
• Intergroup mechanisms have partially succeeded in continuing the LCSG's work.
• Significant challenges remain in replicating the comprehensive framework for clinical investigation previously provided by the LCSG.

Conclusions:

• The closure of the LCSG has had detrimental effects on thoracic oncology research and education.
• While intergroup collaborations offer some continuity, a sustained, dedicated effort is required to re-establish a robust framework for thoracic malignancy clinical investigation.
• Recreating the collaborative infrastructure of the LCSG is crucial for advancing the field.